"Slack" is the biggest security risk
Release time:
2020-07-22
"Slack " is the biggest potential safety hazard
The annual National Safety Production Month has arrived as scheduled. The theme of this year's activity is "to prevent risks, eliminate hidden dangers and prevent accidents " . In the current environment where the whole country attaches great importance to production safety, for most enterprises, safety is a compulsory course for employee induction education, and relevant management institutions and systems are even more indispensable. The words "risk ", "hidden danger " and "accident " are often mentioned, but even so, accidents still occur from time to time. In the first half of this year, there have been many major safety accidents in China, which once again sounded the alarm for the management of production safety. If we carefully analyze these accidents, the causes may be different, but the biggest common point is the slack in ideology.
"Safe production has only a starting point and no ending point " , which is what you will hear in almost every safety education. Around us, safety risks and hidden dangers always exist to varying degrees. In particular, our production enterprises, even if the technology is more advanced, the technology is more perfect, and the experience of the employees is more sophisticated, it is impossible to guarantee 100% safety. In the face of this seemingly cruel reality, the most important key point to achieve safe production is to solve "slack " , "ideological safety hazard " . Because ideology is invisible, if there is such a hidden danger, it will not be as intuitive as the safety hidden danger of "conventional " such as machinery and equipment, production process, etc., and can only be revealed through the specific behavior of people, so it is more difficult to find and eliminate.
To sum up, the specific manifestations of hidden dangers in production safety can be roughly divided into the following categories: formalization of production safety, taking safety work as a show, only grasping the surface, lax implementation, and the form of work is greater than the process; Benefit first, when there is a conflict between safety and production and benefit, production benefit is often put first; Paralysis in a long-term safe state, when the security situation is relatively stable for a long time, relax your vigilance and relax your thinking. Empiricism is lucky, afraid of trouble, trying to save trouble, and thinks that there will be no problems with his rich experience. Departmentalism ignores safety and thinks that grasping safety is a matter for leaders and security officers, which has little to do with oneself. Evading responsibility and covering up, thinking that safety problems and violations are inevitable, as long as they are not found, it is not a problem. In our daily safety management, we often say "three violations " (illegal command, illegal operation, violation of labor discipline), which is the most common manifestation of lax safety thinking.
"Thought rules action, attitude decides everything " . In view of these ideological hidden dangers, if we can not take effective measures, increase education, to raise awareness, solve ideological problems, to achieve safe production can only be empty talk. It should be noted that there is never a buffer period or a rest period for production safety work. Instead, it is always a critical period. Only when every employee can pay attention to it in thought, wake up in consciousness, be rigorous in behavior, and earnestly implement the requirements of safety production from every detail, can the safety of our enterprise be truly guaranteed. (Hong Tao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page